Fate Therapeutics Inc

Fate Therapeutics is an American biopharmaceutical company founded in 2007 and based in San Diego, California. The organisation specialises in the development of programmed cellular immunotherapies for cancer and immune disorders. It serves healthcare professionals across the USA, manufacturing a range of therapies based on their iPSC-derived cell product candidates. Fate Therapeutics bases their cellular immunotherapies on their novel ex vivo cell programming approach. The company started trading publicly on the NASDAQ GS in 2013, using the ticker FATE. In October 2020, the FATE price chart was showing a 52-week low of $12.59 and a 52-week high of $42.22, with a market cap of $3.3bn. The company does not expect to pay any cash or other dividend on its common stock. This innovative and specialist healthcare company collaborates with numerous respected partners, including Janssen Biotech, ONO Pharmaceutical Co., and the Masonic Cancer Centre at the University of Minnesota. These collaborations have led to advancements in the first-ever iPSC-derived cell therapy — FT500 — and the first-ever engineered iPSC-derived cell therapy — FT516. This resulted in the clinical development of these therapies in the United States. If you are interested in FATE stock, you can track this instrument by adding it to your eToro watchlist.